Cannabis and brain health: separating TikTok claims from peptide research

A recent TikTok video by Dr. Bing, MD MPH, poses a broad question: “What can cannabis / marijuana do to your brain?” The clip, aimed at a general audience, implies that cannabis use leads to significant, lasting changes in brain structure and function. While the caption is brief, the underlying claim is that marijuana has well-defined, mostly negative effects on the brain—effects that viewers should be concerned about.

What the research neighborhood actually covers

The scientific literature on cannabis and the brain is extensive but nuanced. Acute effects include altered perception, impaired short-term memory, and increased appetite—mediated primarily by THC binding to CB1 receptors in the central nervous system. Chronic use, especially when started in adolescence, has been associated with changes in brain regions like the prefrontal cortex and hippocampus, which are involved in decision-making and memory. However, the clinical significance of these structural findings is debated, and many studies are confounded by polysubstance use, socioeconomic factors, and genetic predisposition.

On the other hand, CBD—the non-psychoactive component—has been studied for its potential neuroprotective and anti-inflammatory properties, though evidence is still early. The endocannabinoid system itself is a legitimate target for therapeutic research, but the popular narrative often oversimplifies a complex dose-dependent, age-dependent, and compound-specific picture.

Limits, missing context, and what a 15-second clip cannot show

A 15-second TikTok cannot convey the critical distinctions between occasional vs. chronic use, adolescent vs. adult exposure, THC vs. CBD, or smoked vs. edible forms. It also omits the fact that many reported effects are reversible after cessation, and that individual outcomes vary widely. The clip’s broad claim risks fueling stigma without providing actionable, evidence-based nuance. For example, while heavy use is linked to cognitive deficits in some studies, other research shows no significant long-term effects in moderate adult users. Without specifying dosage, frequency, and age of onset, the claim remains an oversimplification.

How this maps to named research compounds

While the clip does not mention peptides, the underlying theme of brain health invites a look at research compounds that are studied for neuroprotection and cognitive support. For instance, BPC-157 has shown promise in animal models for reducing neuroinflammation and promoting neural repair, though human data are lacking. Semax and Selank are synthetic peptides developed in Russia, with some studies suggesting they may enhance cognitive function and reduce anxiety, but again, evidence is preliminary. Cerebrolysin, a peptide preparation, has been investigated for stroke recovery and dementia, but its use is not approved in many countries. It is crucial to note that these compounds are not approved for human use by regulatory agencies like the FDA, and their effects—if any—are not directly comparable to cannabis. The research-use-only context means they are intended for laboratory studies, not self-administration.

Research-use caveat

All peptides discussed are for research purposes only. They are not intended for human consumption, diagnosis, or treatment. The scientific evidence for their efficacy and safety is incomplete, and no clinical recommendations can be made. Researchers must adhere to institutional guidelines and ethical standards when handling these compounds.